Purple Biotech (PPBT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.65M
Last updated: Nov 17, 2026 at 11:03 AM ET
Purple Biotech (PPBT) Earnings: Report Dates and Results
In the quarter ended Jun 30, 2026, Purple Biotech reported EPS of $1.07, above the -$0.98 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
No consensus estimate is on file yet for the quarter ending Dec 31, 2026.
PPBT's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 27 quarters below that had an estimate, PPBT beat 10, missed 12 and matched 5. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 512.45% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $1.07 | -$0.98 | -$0.98 - -$0.98 | +209.18% | Beat | N/A | 1 | 0 up, 1 down | Aug 7, 2026 | N/A |
| Mar 31, 2026 | -$2.33 | -$0.38 | -$0.38 - -$0.38 | -512.45% | Miss | N/A | 1 | 1 up, 0 down | May 15, 2026 | N/A |
| Dec 31, 2025 | -$6.16 | -$3.40 | N/A | -81.18% | Miss | N/A | 1 | 0 up, 0 down | Mar 13, 2026 | N/A |
| Sep 30, 2025 | $2.90 | -$2.60 | -$2.60 - -$2.60 | +211.54% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2025 | N/A |
| Jun 30, 2025 | -$4.00 | -$2.10 | -$2.10 - -$2.10 | -90.48% | Miss | N/A | 1 | 0 up, 0 down | Aug 6, 2025 | N/A |
| Mar 31, 2025 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | May 21, 2025 | N/A |
| Dec 31, 2024 | -$2.71 | -$2.20 | -$2.20 - -$2.20 | -23.18% | Miss | N/A | 1 | 1 up, 0 down | Mar 10, 2025 | N/A |
| Sep 30, 2024 | -$13.67 | -$0.60 | -$0.60 - -$0.60 | N/A | N/A | N/A | 1 | 1 up, 0 down | Nov 15, 2024 | N/A |
| Jun 30, 2024 | -$15.88 | -$26.00 | N/A | +38.92% | Beat | N/A | 2 | 0 up, 0 down | Aug 16, 2024 | N/A |
| Mar 31, 2024 | -$30.26 | -$30.00 | -$46.00 - -$30.00 | -0.87% | Miss | N/A | 2 | 0 up, 0 down | May 21, 2024 | N/A |
| Dec 31, 2023 | -$63.14 | -$34.00 | N/A | -85.71% | Miss | N/A | 3 | 0 up, 0 down | Mar 5, 2024 | N/A |
| Sep 30, 2023 | -$42.02 | -$44.00 | -$50.00 - -$44.00 | +4.50% | Beat | N/A | 3 | 0 up, 0 down | Nov 21, 2023 | N/A |
| Jun 30, 2023 | -$44.22 | -$50.00 | -$74.00 - -$50.00 | +11.56% | Beat | N/A | 3 | 1 up, 0 down | Aug 22, 2023 | N/A |
| Mar 31, 2023 | -$41.60 | -$70.00 | -$74.00 - -$70.00 | +40.57% | Beat | N/A | 2 | 0 up, 0 down | May 16, 2023 | N/A |
| Dec 31, 2022 | -$58.90 | -$50.00 | -$66.00 - -$40.00 | -17.80% | Miss | N/A | 2 | 0 up, 0 down | Feb 8, 2023 | N/A |
| Sep 30, 2022 | -$45.56 | -$42.00 | N/A | -8.48% | Miss | N/A | N/A | N/A | Nov 8, 2022 | N/A |
| Jun 30, 2022 | -$0.20 | -$0.20 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.25 | -$2.00 | N/A | +87.50% | Beat | N/A | N/A | N/A | Feb 9, 2022 | N/A |
| Sep 30, 2021 | -$0.17 | -$0.20 | N/A | +15.00% | Beat | N/A | N/A | N/A | Dec 1, 2021 | N/A |
| Jun 30, 2021 | Not reported | -$0.01 | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 5, 2021 | N/A |
| Mar 31, 2021 | -$76.00 | -$2.00 | N/A | N/A | N/A | N/A | N/A | N/A | Jun 10, 2021 | N/A |
| Dec 31, 2020 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 2, 2021 | $500000 |
| Sep 30, 2020 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Dec 2, 2020 | N/A |
| Jun 30, 2020 | -$0.01 | -$0.01 | N/A | 0.00% | Beat | N/A | N/A | N/A | Aug 11, 2020 | $500000 |
| Mar 31, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 3, 2020 | $500000 |
| Dec 31, 2019 | -$0.30 | -$0.09 | N/A | -233.33% | Miss | N/A | N/A | N/A | Feb 11, 2020 | $1.00M |
| Sep 30, 2019 | Not reported | -$0.13 | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 27, 2019 | N/A |
| Jun 30, 2019 | Not reported | -$0.60 | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 8, 2019 | $500000 |
| Mar 31, 2019 | -$0.19 | -$0.19 | N/A | 0.00% | In line | N/A | N/A | N/A | May 29, 2019 | $500000 |
| Dec 31, 2018 | -$30.00 | -$20.00 | N/A | -50.00% | Miss | N/A | N/A | N/A | Feb 7, 2019 | $1.00M |
| Sep 30, 2018 | Not reported | -$0.01 | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 28, 2018 | N/A |
| Jun 30, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | Beat | N/A | N/A | N/A | Aug 29, 2018 | $500000 |
| Mar 31, 2018 | -$0.10 | -$0.10 | N/A | 0.00% | In line | N/A | N/A | N/A | May 5, 2018 | $500000 |
| Dec 31, 2017 | -$30.00 | -$20.00 | N/A | -50.00% | Miss | N/A | N/A | N/A | Mar 5, 2018 | $50000 |
| Dec 31, 2016 | Not reported | -$0.25 | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 17, 2017 | N/A |
| Sep 30, 2016 | -$2.90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 30, 2016 | N/A |
| Dec 31, 2015 | -$13.10 | -$9.70 | N/A | -35.05% | Miss | N/A | N/A | N/A | Mar 18, 2016 | N/A |
| Sep 30, 2015 | -$19.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 25, 2015 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$7.43, after -$62.52 the year before. It was -$2.90 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$7.43 | N/A |
| Dec 31, 2024 | -$62.52 | N/A |
| Dec 31, 2023 | -$190.98 | N/A |
| Dec 31, 2022 | -$105.07 | N/A |
| Dec 31, 2021 | -$76.42 | N/A |
| Dec 31, 2020 | -$0.07 | N/A |
| Dec 31, 2019 | -$0.49 | N/A |
| Dec 31, 2018 | -$30.11 | N/A |
| Dec 31, 2017 | -$30.00 | N/A |
| Dec 31, 2016 | -$2.90 | N/A |
Frequently Asked Questions About PPBT
Did PPBT beat earnings estimates last quarter?
Yes. Purple Biotech reported EPS of $1.07 for the quarter ended Jun 30, 2026, above the -$0.98 estimate, a 209.18% surprise.
How often does PPBT beat earnings estimates?
Purple Biotech beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -31.06%.
PPBT pages: Overview, Earnings, Forecast, Financials, Competitors